Chloral Hydrate Pediatric Dose — Sedation
Chloral hydrate is a sedative-hypnotic agent that produces CNS depression through its active metabolite, trichloroethanol, acting on GABA receptors. It is used in pediatrics to facilitate sedation for non-painful procedures and diagnostic imaging. Administration is via oral or rectal routes, making it suitable when IV access is not established.
Pediatric Dosing
- Dose: 25–50 mg/kg per dose PO or PR
- Frequency: every 6 hours as needed (PRN)
- Maximum single dose: 1,000 mg (1 g)
Select the dose within the range based on the desired depth of sedation and the clinical context. Higher doses within the range (approaching 50 mg/kg) typically produce deeper sedation but require closer monitoring.
Worked example: For a 20 kg child: 20 × 25 mg/kg = 500 mg (lower end) or 20 × 50 mg/kg = 1,000 mg (upper end, which equals the maximum single dose of 1 g). For a 25 kg child using the upper dose, the calculated 1,250 mg would be capped at the maximum of 1,000 mg per dose.
Indications and Clinical Context
Chloral hydrate is used for procedural sedation in pediatric patients undergoing non-painful diagnostic procedures such as EEG, MRI, CT, and auditory brainstem response (ABR) testing, where minimal movement is required. It is particularly common in infants and young children in whom IV access may be deferred. It is not considered a first-line agent for painful procedures, as it has limited analgesic properties.
Use of chloral hydrate has declined at many institutions given concerns about respiratory depression, prolonged sedation, and lack of a reversal agent. Clinicians should follow institutional sedation protocols and ensure appropriate patient selection prior to administration.
Administration and Monitoring
Chloral hydrate is administered orally (as a solution or capsule) or rectally. The oral route is preferred when feasible. Onset typically occurs within 30–60 minutes of administration. Key monitoring and safety considerations include:
- Continuous pulse oximetry and cardiorespiratory monitoring during and after sedation
- Ensure resuscitation equipment and personnel capable of managing airway complications are available
- Common adverse effects: respiratory depression, paradoxical excitation, nausea, and vomiting
- Prolonged or deep sedation may occur, particularly in neonates and infants; extended post-procedure observation is recommended
- Use with caution in patients with hepatic or renal impairment, as the active metabolite may accumulate
- There is no pharmacologic reversal agent; management of oversedation is supportive
- Consult institutional protocol regarding maximum cumulative daily dosing and minimum NPO requirements prior to elective sedation
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.